Compare Incyte Corporation (INCY) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs First Trust Cloud Computing ETF — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while First Trust Cloud Computing ETF trades at $136.07. The key difference: Incyte Corporation is trading nearer its 52-week high, First Trust Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SKYY | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $155.17 |
52-Week Low | $67.38 | $104.16 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
First Trust Cloud Computing ETF (SKYY) trades at $136.66, up 0.41% with a bullish technical signal from moving averages. The ETF provides diversified exposure to cloud computing companies amid strong sector inflows driven by enterprise AI adoption. Recent news highlights continued institutional interest in technology ETFs, with SKYY positioned as a core holding for cloud computing exposure.
The outlook remains positive as cloud computing benefits from enterprise digital transformation and AI spending acceleration. Key risks include technology sector volatility and competitive pressures from alternative cloud ETFs. Analyst coverage emphasizes SKYY's established track record since 2011 launch and broad market positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
